ArticleAntiviral research2011
Development of Vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression.
Article in Antiviral research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Distinct non-canonical translation initiation modes arise for specific host and viral mRNAs during poxvirus-induced shutoff.Nature microbiology · 2025Article
- A review of Mpox: Biological characteristics, epidemiology, clinical features, diagnosis, treatment, and prevention strategies.Exploration (Beijing, China) · 2025Review
- Ribosome customization and functional diversification among P-stalk proteins regulate late poxvirus protein synthesis.Cell reports · 2025Article
- Evaluation of Vaccinia Virus Infection in Mice Using Two-Reporter Recombinant Virus.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Construction and Isolation of Recombinant Vaccinia Virus by Homologous Recombination Using Fluorescent Protein Markers.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Single-cell analysis of VACV infection reveals pathogen-driven timing of early and late phases and host-limited dynamics of virus production.PLoS pathogens · 2024Article
- Identification of Small Molecules with Improved Potency against Orthopoxviruses from Vaccinia to Smallpox.Antimicrobial agents and chemotherapy · 2022Article
- Poxvirus Recombination.Pathogens (Basel, Switzerland) · 2022Review
- Article
- Bi-Reporter Vaccinia Virus for Tracking Viral InfectionsMicrobiology spectrum · 2021Article
- Vibrational Spectroscopic Detection of a Single Virus by Mid-Infrared Photothermal Microscopy.Analytical chemistry · 2021Article
- Experimental Evolution To Isolate Vaccinia Virus Adaptive G9 Mutants That Overcome Membrane Fusion Inhibition via the Vaccinia Virus A56/K2 Protein Complex.Journal of virology · 2020Article
- The Vaccinia Virus (VACV) B1 and Cellular VRK2 Kinases Promote VACV Replication Factory Formation through Phosphorylation-Dependent Inhibition of VACV B12.Journal of virology · 2019Article
- Activation of stress response pathways promotes formation of antiviral granules and restricts virus replication.Molecular and cellular biology · 2014Article
- Discovery of a novel compound with anti-venezuelan equine encephalitis virus activity that targets the nonstructural protein 2.PLoS pathogens · 2014Article
- Vaccinia reporter viruses for quantifying viral function at all stages of gene expression.Journal of visualized experiments : JoVE · 2014Article
- The master regulator of the cellular stress response (HSF1) is critical for orthopoxvirus infection.PLoS pathogens · 2014Article
- Methodology for the efficient generation of fluorescently tagged vaccinia virus proteins.Journal of visualized experiments : JoVE · 2014Article
- T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Identification of a pyridopyrimidinone inhibitor of orthopoxviruses from a diversity-oriented synthesis library.Journal of virology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Vaccinia virus is the prototypical orthopoxvirus of Poxviridae, a family of viruses that includes the human pathogens Variola (smallpox) and Monkeypox. Core viral functions are conserved among orthopoxviruses, and consequently Vaccinia is routinely used to study poxvirus biology and screen for novel antiviral compounds. Here we describe the development of a series of fluorescent protein-based reporter Vaccinia viruses that provide unprecedented resolution for tracking viral function. The reporter viruses are divided into two sets: (1) single reporter viruses that utilize temporally regulated early, intermediate, or late viral promoters; and (2) multi-reporter viruses that utilize multiple temporally regulated promoters. Promoter and reporter combinations were chosen that yielded high signal-to-background for stage-specific viral outputs. We provide examples for how these viruses can be used in the rapid and accurate monitoring of Vaccinia function and drug action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.